Company Profile For Arena Pharmaceuticals Inc

Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company’s drug candidate, lorcaserin hydrochloride (lorcaserin), is being investigated in a Phase III clinical trial program for the treatment of obesity. It has a pipeline of compounds that target G protein-coupled receptors (GPCRs), and includes compounds being evaluated independently and with its partners, including Merck & Co., Inc. (Merck) and Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil-Janssen). On January 9, 2008, the Company acquired from Siegfried Ltd certain drug product facility assets, including a licensed production facility, fixtures, equipment, other personal property and real estate assets in Zofingen, Switzerland.

BRIEF: For the nine months ended 30 September 2009, Arena Pharmaceuticals, Inc.'s revenues increased 8% to $7.7M. Net loss applicable to Common decreased 30% to $123.4M. Revenues reflect increased income from collaborative agreements. Net loss also reflects lower research & development expenses, decreased general & administrative expenses and lower amortization of acquired technology & other intangible.